文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血管加压素与去甲肾上腺素对实验性脓毒症急性肾损伤肾脏灌注、氧合及功能的益处比较

Beneficial Effects of Vasopressin Compared With Norepinephrine on Renal Perfusion, Oxygenation, and Function in Experimental Septic Acute Kidney Injury.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论在绵羊脓毒症急性肾损伤模型中,血管加压素恢复平均动脉压较去甲肾上腺素更持久改善肾功能,且不加重肾髓质缺血缺氧。

该研究在成年美利奴母羊脓毒症急性肾损伤模型中,比较静脉输注血管加压素(0.03 IU/min [0.03-0.05 IU/min],n=7)与去甲肾上腺素(0.60 μg/kg/min [0.30-0.70 μg/kg/min],n=7)滴定恢复基线平均动脉压对全身血流动力学、肾血流、肾内灌注与氧合及肾功能的影响。脓毒症导致平均动脉压降低16%±2%、肌酐清除率降低65%±9%、肾血流量增加34%±7%,但肾髓质灌注降低44%±7%、氧分压降低47%±10%。血管加压素未显著影响肾髓质灌注或氧分压,并诱导肌酐清除率持续(6小时)约2.5倍增加,还减轻脓毒症诱导的肠系膜充血(从+61%±13降至+9%±6)。去甲肾上腺素短暂(2小时)改善肌酐清除率约3.5倍,但加重肾髓质缺血(至-64%±7%)和缺氧(至-71%±6%)。结论认为,在绵羊脓毒症急性肾损伤中,血管加压素恢复平均动脉压较去甲肾上腺素更持久改善肾功能,且不加重肾髓质缺血缺氧或使肠系膜血流低于基线。

要点

  • 在绵羊脓毒症急性肾损伤模型中,血管加压素(0.03 IU/min [0.03-0.05 IU/min])恢复平均动脉压,使肌酐清除率持续(6小时)约2.5倍增加。
  • 去甲肾上腺素(0.60 μg/kg/min [0.30-0.70 μg/kg/min])仅短暂(2小时)改善肌酐清除率约3.5倍,但加重肾髓质缺血(至-64%±7%)和缺氧(至-71%±6%)。
  • 血管加压素未显著影响肾髓质灌注或氧分压,而去甲肾上腺素使肾髓质灌注和氧分压进一步恶化。
  • 血管加压素减轻脓毒症诱导的肠系膜充血(从+61%±13降至+9%±6),而去甲肾上腺素未报告此效应。
  • 该研究为动物实验,结论需在临床研究中验证,不能直接外推至患者。

适用人群与场景

  • 成年美利奴母羊,通过给予大肠杆菌诱导脓毒症急性肾损伤,在脓毒症24-30小时期间进行干预。

诊断标准与关键阈值

  • 脓毒症急性肾损伤模型特征:平均动脉压降低16%±2%、肌酐清除率降低65%±9%、肾血流量增加34%±7%、肾髓质灌注降低44%±7%、肾髓质氧分压降低47%±10%。

处置流程与药物剂量

  • 血管加压素:0.03 IU/min(范围0.03-0.05 IU/min),静脉输注,滴定至恢复基线平均动脉压,n=7。
  • 去甲肾上腺素:0.60 μg/kg/min(范围0.30-0.70 μg/kg/min),静脉输注,滴定至恢复基线平均动脉压,n=7。

研究设计与关键结果

  • 研究类型:干预性研究,动物实验(绵羊),样本量每组7只,非临床研究。
  • 血管加压素组:肌酐清除率持续(6小时)约2.5倍增加,肾髓质灌注和氧分压无显著变化,肠系膜充血从+61%±13降至+9%±6。
  • 去甲肾上腺素组:肌酐清除率短暂(2小时)改善约3.5倍,但肾髓质缺血加重至-64%±7%、缺氧加重至-71%±6%。
  • 脓毒症急性肾损伤基础特征:平均动脉压降低16%±2%,肌酐清除率降低65%±9%,肾血流量增加34%±7%,肾髓质灌注降低44%±7%,肾髓质氧分压降低47%±10%。

证据类型、等级与局限

  • 证据类型:动物实验(绵羊脓毒症急性肾损伤模型),干预性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在绵羊脓毒症急性肾损伤中,血管加压素恢复平均动脉压较去甲肾上腺素更持久改善肾功能,且不加重肾髓质缺血缺氧或使肠系膜血流低于基线。
  • 该结果为动物实验,不能直接改变急诊/ICU临床实践,需进一步临床研究验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To compare the effects of restoring mean arterial pressure with vasopressin or norepinephrine on systemic hemodynamics, renal blood flow, intrarenal perfusion and oxygenation, and renal function in ovine septic acute kidney injury.

DESIGN: Interventional Study.

SETTING: Research Institute.

SUBJECTS: Adult Merino ewes.

INTERVENTIONS: Flow probes were implanted on the pulmonary and renal arteries (and the mesenteric artery in sheep that received vasopressin). Fiber-optic probes were implanted in the renal cortex and medulla to measure tissue perfusion and oxygen tension (PO2). Conscious sheep were administered Escherichia coli to induce septic acute kidney injury. Vasopressin (0.03 IU/min [0.03-0.05 IU/min]; n = 7) or norepinephrine (0.60 μg/kg/min [0.30-0.70 μg/kg/min]; n = 7) was infused IV and titrated to restore baseline mean arterial pressure during 24-30 hours of sepsis.

MEASUREMENTS AND MAIN RESULTS: Ovine septic acute kidney injury was characterized by reduced mean arterial pressure (-16% ± 2%) and creatinine clearance (-65% ± 9%) and increased renal blood flow (+34% ± 7%) but reduced renal medullary perfusion (-44% ± 7%) and PO2 (-47% ± 10%). Vasopressin infusion did not significantly affect renal medullary perfusion or PO2 and induced a sustained (6 hr) ~2.5-fold increase in creatinine clearance. Vasopressin reduced sepsis-induced mesenteric hyperemia (+61 ± 13 to +9% ± 6%). Norepinephrine transiently (2 hr) improved creatinine clearance (by ~3.5-fold) but worsened renal medullary ischemia (to -64% ± 7%) and hypoxia (to -71% ± 6%).

CONCLUSIONS: In ovine septic acute kidney injury, restoration of mean arterial pressure with vasopressin induced a more sustained improvement in renal function than norepinephrine, without exacerbating renal medullary ischemia and hypoxia or reducing mesenteric blood flow below baseline values.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Okazaki N, Iguchi N, Evans RG, et al. Beneficial Effects of Vasopressin Compared With Norepinephrine on Renal Perfusion, Oxygenation, and Function in Experimental Septic Acute Kidney Injury. Crit Care Med. 2020. PMID: 32931198. doi:10.1097/CCM.0000000000004511

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。